Sponsorsview all sponsors
MSHO continuously contacts legislators, provides comments to policy makers and collaborates with payers on issues of concern to those delivering care to cancer patients.
It is important that our members are aware of meetings, web casts, and other educational opportunities specifically designed to address the complexities of cancer care.
Stivarga (regorafenib) approved for GIST
The FDA approved Stivarga (regorafenib) tablets to treat patients with locally advanced, unresectable or metastatic GIST who have been previously treated with imatinib mesylate and sunitinib malate. READ MORE